Press Releases

Exercise of Warrants

By December 22, 2015January 26th, 2016No Comments

Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company will issue 35,925 ordinary shares of 1 penny each (“Option Shares”)  in settlement of options that have been exercised.  The options were exercised at a price of US $0.20 per ordinary share for total consideration of US $7,185.

Admission to trading on AIM (“Admission”) of the Option Shares, which will rank pari passu with the existing Ordinary Shares, will be applied for, and it is expected that Admission will become effective and dealings in the new Ordinary Shares will commence on 29 December 2015.

Total Voting Rights

Following Admission, the total issued share capital of the Company will be 108,601,496 Ordinary Shares with one voting right each. The Company does not hold any shares in treasury.

Accordingly, the total voting rights in the Company will be 108,601,496. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules of the UK Financial Conduct Authority.


Motif Bio plc

Graham Lumsden, Chief Executive Officer
[email protected]

Zeus Capital Limited (Nominated Advisor and Broker)

Phil Walker / Dan Bate
Dominic Wilson
+44 (0) 20 3829 5000

Northland Capital Partners (Broker)

Patrick Claridge / David Hignell
John Howes / Mark Treharne (Broking)
+44 (0) 207 382 1100

MC Services AG (Trade PR)

Raimund Gabriel
Shaun Brown
+49 (0) 89 210 2280
+44 (0) 207 148 5998

Plumtree Capital Limited (Financial Advisor)

Stephen Austin
+44 (0) 207 183 2493

Yellow Jersey PR (Financial PR)

Charles Goodwin
Dominic Barretto
+44 (0) 7747 788 221

Notes to Editors

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus).  Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.  For additional information about Motif please visit